292 results about "Psoriasis" patented technology

The invention discloses hydrogel loaded with antibacterial polypeptide as well as a preparation method and application of the hydrogel. The preparation method of the hydrogel comprises the steps that antibacterial polypeptide and polyethylene glycol dimethacrylate are subjected to a cross-linking reaction, the hydrogel can be obtained, and the antibacterial polypeptide is obtained through polymerization synthesis of a cationic CBL monomer compound and an HBL monomer compound; the hydrogel has remarkable sterilization and anti-biofilm effects, and in-vitro cytotoxicity shows that the antibacterial polypeptide hydrogel product has no inhibition effect on normal cell growth; when the hydrogel dressing is used as a hydrogel dressing and is combined with novobiocin for use, more than 99% of antibacterial effect is achieved in a diabetes wound infection model and a fungal psoriasis infection model; and when being used as a hydrogel preparation to be combined with fluconazole, the compound has the effect of inhibiting growth of more than 99% of fungi in an animal vaginitis model.

The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

A perilla leaf-derived nanovesicle and the use thereof in the preparation of a product with anti-inflammatory efficacy. The nanovesicle can be phagocytosed and internalized by HaCaT cells, reduce the levels of ROS and inflammatory factors in HaCaT cells, and exert an anti-inflammatory effect. Meanwhile, the nanovesicle has excellent transdermal properties, and thus can effectively alleviate and treat psoriatic dermatitis symptoms in mice. The nanovesicle can also be added as an active ingredient to different matrices to form compositions.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

The invention discloses application of pedunculoside in preparation of a medicine for treating psoriasis, and relates to the technical field of medicines. The invention provides a natural candidate drug which is clear in structure and has both effectiveness and safety for clinical treatment of psoriasis.

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention discloses a pharmaceutical composition for treating psoriasis and application thereof. The active ingredient of the composition is a combination of Mongolian medicine seven-ingredient powder soup and a horse bone extracting solution, wherein the Mongolian medicine seven-ingredient powder is prepared from radix sophorae flavescentis, elecampane, fructus chebulae, szechwan chinaberry fruit, fructus gardeniae, herba violae and rhizoma picrorhizae according to a specific proportion. The preparation method of the composition mainly comprises the following steps: respectively preparing Mongolian medicine seven-component powder soup and horse bone extracting solution, and then mixing and decocting the Mongolian medicine seven-component powder soup and the horse bone extracting solution. Through the synergistic interaction of the Mongolian medicine seven-ingredient powder decoction and the horse bone extracting solution, the composition shows a treatment effect superior to that of independent use of each component in an animal model, and can remarkably relieve psoriasis-like skin lesion and down-regulate the expression of related inflammatory factors. The invention provides an application of the composition in preparation of a medicine for treating psoriasis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

The invention relates to application of oxymatrine in preparation of a medicine for treating a patient suffering from erythroderma psoriasis and the like.

Disclosed is use of danshensu or a pharmaceutically acceptable salt thereof as a PI3K / AKT / mTOR signaling pathway inhibitor in the preparation of a drug for treating psoriasis. Pharmacological experiments reveal that danshensu can inhibit the phosphorylation of the PI3K / AKT / mTOR signaling pathway to significantly ameliorate psoriasis-like skin lesions on mice and reduce the excessive proliferation and abnormal differentiation of epidermal cells and the expression of CCL20mRNA in skin lesions. In vitro experiments show that danshensu can inhibit TNF-α-induced HaCaT cell proliferation and inhibit the generation and secretion of the pro-inflammatory factors IL-6, IL-8, and IFN-γ and the chemokine CCL20. The use of danshensu to prepare a drug for treating psoriasis opens up a new field of application for danshensu.

The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention concerns methods and pharmaceutical compositions for use in the treatment of psoriasis comprising as an active ingredient piclidenoson (IB-MECA) in an amount suitable for a daily dose administration of about 6 milligrams (mg).

The invention provides a preparation method of traditional Chinese medicine hydrogel for treating psoriasis, the hydrogel preparation is prepared from the following raw material medicines in parts by weight: 20-40 parts of PVA, 60-80 parts of borax, 20-40 parts of glycyrrhizic acid, 8-12 parts of paeoniflorin and 2-3 parts of glycerin, the hydrogel has the advantages of injectability, self-healing, stretchability and the like, can meet the requirements of skin dressing, can be tightly attached to the skin, and has a good application prospect. The separation is easy. Animal experiments prove that after being loaded with paeoniflorin, the gel has the curative effect of treating mild and moderate psoriasis, the treatment effect is remarkable, and the gel has a wide market application prospect.

The present invention relates to a peptide inhibitor of an interleukin-23 receptor and a use thereof. In particular, the present invention relates to peptide inhibitors of the interleukin-23 receptor, stereoisomers or pharmaceutically acceptable salts or solvates thereof, pharmaceutical compositions thereof, and uses of the peptide inhibitors in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

This invention discloses a class of PDE4 degrading agents or their pharmaceutical salts for treating psoriasis, with a general structural formula selected from one of the following structures: The PDE4 degrading agents for treating psoriasis provided by this invention offer a new strategy for in-depth research and development of novel structural types of anti-psoriasis drugs. The compounds of this invention exhibit excellent in vitro degradation activity against PDE4 protein.

The present invention relates to a flexible skin patch equipped with an ultra-thin LED assembly that emits light in a specific wavelength range and an invention for manufacturing the same, and is related to an invention capable of providing a flexible skin patch that has the excellent effect of promoting vitamin D production in a localized area of the skin, and has the effect of alleviating or treating local skin psoriasis, fungi, fungal tumors and eczema, and has excellent antiviral effect, and is easy to attach and detach.

Provided are a novel peptide inhibitor of the interleukin-23 receptor, a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same, and the use of the peptide inhibitor in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

The present invention relates to a peptide inhibitor of interleukin-23 receptor, and a use thereof. In particular, it relates to a peptide inhibitor of interleukin-23 receptor, a stereoisomer, pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition thereof, and a use of the peptide inhibitor in treating or preventing diseases or conditions comprising inflammatory bowel disease, Crohn's disease, and psoriasis.

1. Name of the product in this design: Ultraviolet Phototherapy Device (308 nm). 2. Intended use of this design: Treatment of psoriasis and vitiligo. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

Sesterterpenoid compounds and an extract L01 of Leucosceptrum canum, and use thereof in treatment of psoriasis are provided, belonging to the technical field of natural medicinal chemistry. The sesterterpenoid compound of the Leucosceptrum canum has a structure shown in any one of Formulas 9 to 12, which shows a highly rare backbone type, exhibits anti-inflammatory and immunosuppressive activities, and can be used in preparation of an anti-inflammatory drug and an immunosuppressive drug. A Leucosceptrum canum extract L01 having compounds 1 to 12 as characteristic ingredients, and use thereof in preparation of an anti-inflammatory drug and an immunosuppressive drug are further provided.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

The present invention relates to a polymer self-assembly nanocarrier and a method of preparing same, the nanocarrier binding a peptide that targets a specific cell and, simultaneously, carrying an active ingredient that has been verified. The present invention can exhibit various effects such as a moisturizing effect, an increase in filaggrin production, whitening, skin barrier reinforcement and the like by selectively and efficiently delivering a drug through a targeting peptide, can be applied to skin diseases such as atopy or psoriasis, and is expected to enable the maximum effect of an active substance in the pharmaceutical and cosmetic fields to be obtained.

The invention relates to a preparation technology of composite pickles pickled in a soil jar. The composite pickles comprise the following raw materials: stems of psoriasis, a taste raw material, a flavor raw material and pre-prepared saline water. The process comprises the following steps: firstly, carrying out special treatment on the leaf beet stems: removing green leaves at the tail ends, repeatedly washing for three times to remove astringency, washing and cutting together with the taste raw materials, and airing until the surfaces do not have obvious moisture; the weight of the psoriasis is 10% of the weight of the psoriasis, the psoriasis is uniformly grabbed and kneaded, the materials are placed in a shade place for standing, then the psoriasis stems, the taste raw materials and the flavor raw materials are sequentially placed in an earth jar, the prefabricated saline water is added, the materials are sealed with water and naturally fermented, the storage temperature is controlled to be 16-20 DEG C, and the materials are stored for 24-24 hours. The overall fermentation time is greater than or equal to 180 days. According to the process, the psoriasis can keep crisp and tender mouth feel, the psoriasis and other raw materials form rich-level crisp feel, the composite flavor is coordinated, fermentation is stable, and finally the composite pickle which is high in mouth feel, full in flavor and stable in quality is obtained.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating psoriasis, a preparation method and application thereof. The raw material composition comprises, in mass parts, 10-30 parts of schizonepeta, 10-30 parts of moxa leaf, and 10-30 parts of rhizoma alocasia. Animal experiments show that the traditional Chinese medicine composition can promote the repair of skin barrier function and reduce the skin lesion symptoms of psoriasis-like mice, which indicates that the traditional Chinese medicine composition has a good therapeutic effect on psoriasis.

The invention discloses a targeting peptide for blocking combination of IL-17A and IL-17RA / RC and application thereof, the targeting peptide is selected from AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 or a combination of any one of AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 and IBP, the amino acid sequence of AZS-1 is as shown in SEQ ID NO: 1, the amino acid sequence of AZS-2 is as shown in SEQ ID NO: 2, the amino acid sequence of AZS-3 is as shown in SEQ ID NO: 3, the amino acid sequence of AZS-4 is as shown in SEQ ID NO: 4, and the amino acid sequence of AZS-5 is as shown in SEQ ID NO: 5. The amino acid sequence of the AZS-5 is as shown in SEQ ID NO: 5, and the amino acid sequence of the IBP is as shown in SEQ ID NO: 6. The targeting peptide provided by the invention has good tolerance, can generate effective interaction with the surface of a target protein, can realize specific binding with IL-17A, has relatively high blocking ability, can effectively improve symptoms of liver and kidney cell injury, cell edema and skin injury caused by psoriasis after being applied to a psoriasis mouse model, and has a good application prospect. The compound has a good application prospect in treatment and / or adjuvant therapy of IL-17A-mediated inflammatory diseases.

The present invention relates to methods of administering a cyclic peptide inhibitor of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding compositions, assays, methods, and / or uses for treatment of psoriasis.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating psoriasis. The structure of the CD177 targeting membrane modified liposome comprises a PADI4 inhibitor loaded liposome, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the liposome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. Based on the core pathological mechanism of 'CD177 + neutrophil-NETs' of psoriasis, the inflammation chemotaxis / cell factor neutralization function of a neutrophil membrane, the precise targeting function of CD177 peptide and the NETs inhibition function of a PADI4 inhibitor are creatively and organically integrated, and the constructed GNLC achieves the synergistic treatment effect of 'targeting enrichment-mechanism blocking-microenvironment remodeling'; meanwhile, excellent stability and safety are achieved, and a new precise treatment strategy far better than that in the prior art is provided for psoriasis.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.